Quantifying and reducing uncertainties in cancer therapy

Harrison H Barrett, David S Alberts, James M. Woolfenden, Zhonglin Liu, Luca Caucci, John W. Hoppin

Research output: Chapter in Book/Report/Conference proceedingConference contribution

4 Citations (Scopus)

Abstract

There are two basic sources of uncertainty in cancer chemotherapy: how much of the therapeutic agent reaches the cancer cells, and how effective it is in reducing or controlling the tumor when it gets there. There is also a concern about adverse effects of the therapy drug. Similarly in external-beam radiation therapy or radionuclide therapy, there are two sources of uncertainty: delivery and efficacy of the radiation absorbed dose, and again there is a concern about radiation damage to normal tissues. The therapy operating characteristic (TOC) curve, developed in the context of radiation therapy, is a plot of the probability of tumor control vs. the probability of normal-tissue complications as the overall radiation dose level is varied, e.g. by varying the beam current in external-beam radiotherapy or the total injected activity in radionuclide therapy. The TOC can be applied to chemotherapy with the administered drug dosage as the variable. The area under a TOC curve (AUTOC) can be used as a figure of merit for therapeutic efficacy, analogous to the area under an ROC curve (AUROC), which is a figure of merit for diagnostic efficacy. In radiation therapy AUTOC can be computed for a single patient by using image data along with radiobiological models for tumor response and adverse side effects. In this paper we discuss the potential of using mathematical models of drug delivery and tumor response with imaging data to estimate AUTOC for chemotherapy, again for a single patient. This approach provides a basis for truly personalized therapy and for rigorously assessing and optimizing the therapy regimen for the particular patient. A key role is played by Emission Computed Tomography (PET or SPECT) of radiolabeled chemotherapy drugs.

Original languageEnglish (US)
Title of host publicationProgress in Biomedical Optics and Imaging - Proceedings of SPIE
PublisherSPIE
Volume9412
ISBN (Print)9781628415025
DOIs
StatePublished - 2015
EventMedical Imaging 2015: Physics of Medical Imaging - Orlando, United States
Duration: Feb 22 2015Feb 25 2015

Other

OtherMedical Imaging 2015: Physics of Medical Imaging
CountryUnited States
CityOrlando
Period2/22/152/25/15

Fingerprint

Chemotherapy
Radiotherapy
Uncertainty
Tumors
therapy
cancer
chemotherapy
Radioisotopes
radiation therapy
Dosimetry
tumors
Neoplasms
Drug dosage
curves
Drug Therapy
Tissue
drugs
Drug therapy
Radiation damage
figure of merit

Keywords

  • Chemotherapy
  • Normal tissue complications
  • Personalized medicine
  • PET
  • Precision medicine
  • Radiation therapy
  • SPECT
  • Therapy operating characteristic
  • Tumor control

ASJC Scopus subject areas

  • Atomic and Molecular Physics, and Optics
  • Electronic, Optical and Magnetic Materials
  • Biomaterials
  • Radiology Nuclear Medicine and imaging

Cite this

Barrett, H. H., Alberts, D. S., Woolfenden, J. M., Liu, Z., Caucci, L., & Hoppin, J. W. (2015). Quantifying and reducing uncertainties in cancer therapy. In Progress in Biomedical Optics and Imaging - Proceedings of SPIE (Vol. 9412). [94120N] SPIE. https://doi.org/10.1117/12.2189093

Quantifying and reducing uncertainties in cancer therapy. / Barrett, Harrison H; Alberts, David S; Woolfenden, James M.; Liu, Zhonglin; Caucci, Luca; Hoppin, John W.

Progress in Biomedical Optics and Imaging - Proceedings of SPIE. Vol. 9412 SPIE, 2015. 94120N.

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Barrett, HH, Alberts, DS, Woolfenden, JM, Liu, Z, Caucci, L & Hoppin, JW 2015, Quantifying and reducing uncertainties in cancer therapy. in Progress in Biomedical Optics and Imaging - Proceedings of SPIE. vol. 9412, 94120N, SPIE, Medical Imaging 2015: Physics of Medical Imaging, Orlando, United States, 2/22/15. https://doi.org/10.1117/12.2189093
Barrett HH, Alberts DS, Woolfenden JM, Liu Z, Caucci L, Hoppin JW. Quantifying and reducing uncertainties in cancer therapy. In Progress in Biomedical Optics and Imaging - Proceedings of SPIE. Vol. 9412. SPIE. 2015. 94120N https://doi.org/10.1117/12.2189093
Barrett, Harrison H ; Alberts, David S ; Woolfenden, James M. ; Liu, Zhonglin ; Caucci, Luca ; Hoppin, John W. / Quantifying and reducing uncertainties in cancer therapy. Progress in Biomedical Optics and Imaging - Proceedings of SPIE. Vol. 9412 SPIE, 2015.
@inproceedings{2071c964a6e5461cb7b61776e9460047,
title = "Quantifying and reducing uncertainties in cancer therapy",
abstract = "There are two basic sources of uncertainty in cancer chemotherapy: how much of the therapeutic agent reaches the cancer cells, and how effective it is in reducing or controlling the tumor when it gets there. There is also a concern about adverse effects of the therapy drug. Similarly in external-beam radiation therapy or radionuclide therapy, there are two sources of uncertainty: delivery and efficacy of the radiation absorbed dose, and again there is a concern about radiation damage to normal tissues. The therapy operating characteristic (TOC) curve, developed in the context of radiation therapy, is a plot of the probability of tumor control vs. the probability of normal-tissue complications as the overall radiation dose level is varied, e.g. by varying the beam current in external-beam radiotherapy or the total injected activity in radionuclide therapy. The TOC can be applied to chemotherapy with the administered drug dosage as the variable. The area under a TOC curve (AUTOC) can be used as a figure of merit for therapeutic efficacy, analogous to the area under an ROC curve (AUROC), which is a figure of merit for diagnostic efficacy. In radiation therapy AUTOC can be computed for a single patient by using image data along with radiobiological models for tumor response and adverse side effects. In this paper we discuss the potential of using mathematical models of drug delivery and tumor response with imaging data to estimate AUTOC for chemotherapy, again for a single patient. This approach provides a basis for truly personalized therapy and for rigorously assessing and optimizing the therapy regimen for the particular patient. A key role is played by Emission Computed Tomography (PET or SPECT) of radiolabeled chemotherapy drugs.",
keywords = "Chemotherapy, Normal tissue complications, Personalized medicine, PET, Precision medicine, Radiation therapy, SPECT, Therapy operating characteristic, Tumor control",
author = "Barrett, {Harrison H} and Alberts, {David S} and Woolfenden, {James M.} and Zhonglin Liu and Luca Caucci and Hoppin, {John W.}",
year = "2015",
doi = "10.1117/12.2189093",
language = "English (US)",
isbn = "9781628415025",
volume = "9412",
booktitle = "Progress in Biomedical Optics and Imaging - Proceedings of SPIE",
publisher = "SPIE",

}

TY - GEN

T1 - Quantifying and reducing uncertainties in cancer therapy

AU - Barrett, Harrison H

AU - Alberts, David S

AU - Woolfenden, James M.

AU - Liu, Zhonglin

AU - Caucci, Luca

AU - Hoppin, John W.

PY - 2015

Y1 - 2015

N2 - There are two basic sources of uncertainty in cancer chemotherapy: how much of the therapeutic agent reaches the cancer cells, and how effective it is in reducing or controlling the tumor when it gets there. There is also a concern about adverse effects of the therapy drug. Similarly in external-beam radiation therapy or radionuclide therapy, there are two sources of uncertainty: delivery and efficacy of the radiation absorbed dose, and again there is a concern about radiation damage to normal tissues. The therapy operating characteristic (TOC) curve, developed in the context of radiation therapy, is a plot of the probability of tumor control vs. the probability of normal-tissue complications as the overall radiation dose level is varied, e.g. by varying the beam current in external-beam radiotherapy or the total injected activity in radionuclide therapy. The TOC can be applied to chemotherapy with the administered drug dosage as the variable. The area under a TOC curve (AUTOC) can be used as a figure of merit for therapeutic efficacy, analogous to the area under an ROC curve (AUROC), which is a figure of merit for diagnostic efficacy. In radiation therapy AUTOC can be computed for a single patient by using image data along with radiobiological models for tumor response and adverse side effects. In this paper we discuss the potential of using mathematical models of drug delivery and tumor response with imaging data to estimate AUTOC for chemotherapy, again for a single patient. This approach provides a basis for truly personalized therapy and for rigorously assessing and optimizing the therapy regimen for the particular patient. A key role is played by Emission Computed Tomography (PET or SPECT) of radiolabeled chemotherapy drugs.

AB - There are two basic sources of uncertainty in cancer chemotherapy: how much of the therapeutic agent reaches the cancer cells, and how effective it is in reducing or controlling the tumor when it gets there. There is also a concern about adverse effects of the therapy drug. Similarly in external-beam radiation therapy or radionuclide therapy, there are two sources of uncertainty: delivery and efficacy of the radiation absorbed dose, and again there is a concern about radiation damage to normal tissues. The therapy operating characteristic (TOC) curve, developed in the context of radiation therapy, is a plot of the probability of tumor control vs. the probability of normal-tissue complications as the overall radiation dose level is varied, e.g. by varying the beam current in external-beam radiotherapy or the total injected activity in radionuclide therapy. The TOC can be applied to chemotherapy with the administered drug dosage as the variable. The area under a TOC curve (AUTOC) can be used as a figure of merit for therapeutic efficacy, analogous to the area under an ROC curve (AUROC), which is a figure of merit for diagnostic efficacy. In radiation therapy AUTOC can be computed for a single patient by using image data along with radiobiological models for tumor response and adverse side effects. In this paper we discuss the potential of using mathematical models of drug delivery and tumor response with imaging data to estimate AUTOC for chemotherapy, again for a single patient. This approach provides a basis for truly personalized therapy and for rigorously assessing and optimizing the therapy regimen for the particular patient. A key role is played by Emission Computed Tomography (PET or SPECT) of radiolabeled chemotherapy drugs.

KW - Chemotherapy

KW - Normal tissue complications

KW - Personalized medicine

KW - PET

KW - Precision medicine

KW - Radiation therapy

KW - SPECT

KW - Therapy operating characteristic

KW - Tumor control

UR - http://www.scopus.com/inward/record.url?scp=84943329839&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943329839&partnerID=8YFLogxK

U2 - 10.1117/12.2189093

DO - 10.1117/12.2189093

M3 - Conference contribution

SN - 9781628415025

VL - 9412

BT - Progress in Biomedical Optics and Imaging - Proceedings of SPIE

PB - SPIE

ER -